By:
On:
In: CGRP

Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.Read More →

By:
On:
In: CGRP

In June, Teva of Petach Tikva, Israel, paid $200 million in cash and $625 million in future milestones to acquire Labrys Biologics of San Mateo, California. The Israeli drug maker wanted to get its hands on LBR-101, the biotech’s preventive treatment for migraines and its only asset. LBR-101, a humanized monoclonal a…Read More →